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Abstract: Thiomaltol, a potential S,O-coordinating molecule,
has been utilized for the complexation of four different or-
ganometallic fragments, yielding the desired RuII, OsII, RhIII,
and IrIII complexes having a “piano-stool” configuration. In
addition to the synthesis of these compounds with a chlorido
leaving group, the analogous 1-methylimidazole derivatives
have been prepared, giving rise to thiomaltol-based organo-
metallics with enhanced stability under physiological condi-
tions. The organometallic compounds have been character-
ized by NMR spectroscopy, elemental analysis, and X-ray dif-
fraction analysis. Their behavior in aqueous solution and
their interactions with certain amino acids have been stud-
ied by ESI mass spectrometry. Their pH-dependent stability
has been investigated by 1H NMR in aqueous solution, and
their cytotoxicity against three different cancer cell lines has
been investigated. Furthermore, their capacity as topoiso-
merase IIa inhibitors as well as their effect on the cell cycle
distribution and reactive oxygen species (ROS) generation
have been elucidated.
Introduction
In recent years, the development of ruthenium-containing
compounds has expanded the spectrum of potential antican-
cer drugs. Considerable impetus has arisen due to the occur-
rence of a variety of resistances to treatment of different
cancer types with commonly applied platinum-based single-
agent or combination chemotherapy strategies.[1] One promis-
ing drug candidate featuring a ruthenium core is IT-139
(Figure 1); it was thoroughly studied in a phase I clinical trial,
in which it demonstrated activity against different tumor
types. It was shown that this RuIII-based drug could be applied
in the treatment of non-pancreatic gastrointestinal neuroendo-
crine tumors, where it influences the GRP78 pathway. GRP78,
a regulator of endoplasmic reticulum stress response, has been
found to be significantly upregulated in cancer cells and is ac-
credited with a high impact on tumor cell survival and resist-
ance.[2] Furthermore, evidence for synergy of IT-139 was ob-
tained when it was tested in combination with approved anti-
cancer drugs, such as sorafenib.[3] NAMI-A, as another represen-
tative of ruthenium(III) anticancer compounds, showed a diver-
gent activity profile compared to IT-139, despite its structural
similarities. Even though this drug demonstrated selective ac-
tivity in metastatic cells and antiangiogenic activity,[4, 5] clinical
trials were discontinued due to poor clinical responses and the
absence of a distinctly assignable target.[6] Besides ruthe-
nium(III) compounds, the development of organometallic com-
plexes that contain the metal in its reduced, active form, stabi-
lized by the coordination of an arene ligand to the metal
center, has emerged in the field of anticancer drug research.[7]
Two representatives of this group of ruthenium(II) organo-
metallic compounds are RAPTA-C and RM175, which have
been extensively studied in the course of various preclinical in-
vestigations.[7–9]
Ruthenium(II) half-sandwich complexes provide a promising
approach for the development of anticancer metallodrugs with
different modes of action. The impact of ligand variation on
the most important characteristics of these compounds has
been an active field of research and, through a series of stud-
ies, it was demonstrated that the nature of the donor atoms
has a considerable impact on the in vitro activity.[10] Low anti-
cancer activities could be explained by insufficient complex
stability due to replacement of the active ligand by biomole-
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cules, which are omnipresent once the drug has been adminis-
tered. A thorough investigation and comparison of maltol-de-
rived ruthenium(II) complexes by NMR and ESI-MS supported
the assumption that the replacement of an O,O-donor set by
an S,O-donating moiety could increase both aqueous stability
and cytotoxic activity, resulting in IC50 values in the low mm
range.[11,12] The stronger bond between the metal center and
the ligand can be attributed to the softer character of the
sulfur atom in comparison to oxygen, which should result in
an increased complex stability since ligand-exchange reactions
and subsequent inactivation are impeded.[13] As illustrated pre-
viously, co-incubation of imidazole with the organoruthe-
nium(II) maltolato complex greatly increased the stability of
the complex due to a decelerated aquation process.[12] Since
this ligand exchange by a water molecule is thought to be di-
rectly related to the activity of a compound, a delayed activa-
tion is desired in order to allow for accumulation of the intact
drug and subsequent interaction with the cellular target. In
this work, we demonstrate that coordination of 1-methylimida-
zole (MeIm) stabilizes the complexes under alkaline conditions,
while at the same time offering an interesting approach to-
wards complex activation at the slightly acidic pH values pres-
ent in tumor tissues.[14,15] In addition, we have investigated the
impacts of metal center and leaving group variation on the
physicochemical and biological properties. Preliminary studies
have been conducted concerning possible cellular targets, and
possible modes of action have been elucidated by investiga-
tion of topoisomerase IIa inhibition, reactive oxygen species
(ROS) production, and cell cycle analysis.
Results and Discussion
The introduction of an imidazole moiety in place of a chlorido
ligand should increase the stability of complexes in the pres-
ence of biomolecules, as well as their solubility, depending on
the counter ion of the resulting charged organometallic. Com-
mercially available maltol was used as starting point for this
synthetic pathway and was converted to its thionated ana-
logue by reaction with Lawesson’s reagent under inert condi-
tions. Complexation was performed under the established re-
action conditions.[16,17] The first approach was the direct con-
version of 1a–d (Scheme 1) by the addition of silver trifluoro-
methanesulfonate and 1-methylimidazole. However, this at-
tempt resulted in the formation of compound mixtures that
could not be separated. Therefore, a different strategy was ap-
plied, involving [bis(1-methylimidazole)M(p-cym/Cp*)Cl]Cl (p-
cym=p-cymene) precursor complexes. In contrast to the situa-
tion with the mono-imidazole analogue, only one product was
obtained after treatment with thiomaltol. The four required
bis(1-methylimidazole) precursors were synthesized by treat-
ment of the respective dimeric metal compounds [M(p-cym/
Cp*)Cl2]2 (M=Ru
II, OsII, RhIII, IrIII) with a slight excess of 1-meth-
ylimidazole under optimized microwave reaction conditions
(Scheme 1).[18] In general, coordination of thiomaltol to organo-
metallic moieties requires strictly inert conditions to avoid the
formation of undesired by-products. Therefore, the complexa-
tion reactions were performed in distilled methanol by means
of Schlenk-line techniques. Thiomaltol was deprotonated by
using sodium methoxide in dry methanol. After addition of the
respective dimeric metal precursor, the reaction mixture was
stirred at room temperature for 1.5–24 h, depending on the
metal center present. Extraction with dichloromethane and
subsequent filtration allowed the isolation of pure complexes.
The desired products were obtained by crystallization from di-
chloromethane/diethyl ether in low to moderate yields (32–
52%). The isolated complexes were characterized by standard
analytical methods, such as 1H and 13C NMR, elemental analysis,
ESI-MS measurements, and, where possible, by X-ray diffraction
analysis. 1H NMR spectra of both the chlorido series as well as
of the complexes with 1-methylimidazole were recorded from
solutions in deuterated methanol and showed characteristic
signals (see Figures S1–S4). The chlorido compounds showed
only two doublets attributable to the aromatic protons of the
h6-p-cymene ligand, although four distinct signals could be ex-
pected due to the magnetically inequivalent protons. This
effect has also been observed for similar maltolato-based orga-
noruthenium(II) and osmium(II) complexes.[19] Substitution by
the more sterically demanding 1-methylimidazole moiety leads
to a more complex NMR spectrum, which could be rationalized
in terms of hindered inversion at the metal center. ESI-MS stud-
ies showed complexes 2a–d to be more stable than their
chlorido analogues 1a–d under the applied conditions. 1a–d
and 2c,d formed only [MCl]+ or [MMeIm]+ fragments,
whereas complexes 2a,b showed signals attributable to the
molecular peak [M]+ and [MMeIm]+ .
Figure 1. Important representatives of ruthenium-containing compounds as anticancer agents. From left to right: A) IT-139 (NKP-1339), B) NAMI-A, C) RAPTA-
C, and D) RM175.
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X-ray diffraction analysis
Single crystals of 1b and 1c (Figure 2) as well as of 2a–d (Fig-
ures 3, and Figures S6 and S8 in the Supporting Information)
suitable for X-ray diffraction analysis were obtained by precipi-
tation from dichloromethane/n-hexane or dichloromethane/di-
ethyl ether. The crystal structure of 1a has been published pre-
viously.[12] All of the complexes adopt the so-called “piano-
stool” configuration, whereby the stabilizing aromatic ligand
forms the seat and the chelating thiomaltolato ligand as well
as the respective leaving group (either chlorido or 1-methyl-
imidazole) constitute the chair legs. Upon coordination of thio-
maltol to organometallic fragments, a distorted nonplanar five-
membered ring was formed with an O-M-S-C torsion angle
ranging from 2.53 to 10.698. The distortion can be explained
by the pronounced difference in bond lengths of the metal ion
to the oxygen and sulfur donor atoms [1a : 2.080 and 2.373 ;
RuII maltolato complex: 2.082(3) and 2.108(3) ,[4] respectively] .
The most salient bond lengths and angles in 1b and 1c are
summarized in Table 1. Both complexes are representatives of
the monoclinic crystal system, with 1b belonging to the space
group P21/c, whereas 1c crystallizes in the space group C2/c.
The MCl distances were found to lie in the same range for
both the OsII (1b) and RhIII (1c) complexes [1b : 2.4357 ; 1c :
2.4222 ], in good agreement with reported data for 1a
[2.433 ].[11,12] The CS bond lengths in 1b and 1c were found
to be slightly longer than in the free ligand [1b : 1.7035 , 1c :
1.7032 , L1: 1.6770 ][2] due to the electron-withdrawing
effect of the coordinated metal.
By comparison of 2a–d, structural similarity between the OsII
and RuII compounds as well as between the IrIII and RhIII com-
plexes can be observed. Complexes 2a and 2b are representa-
tives of the triclinic P1¯ space group, whereas compounds 2c
and 2d belong to the monoclinic space group P21/c. The
metal-azole distance ranges from 2.0981  in 2a to 2.1024  in
2d. The measured metal-azole bond lengths are in good
agreement with reported data for the corresponding precursor
complex [(p-cym)Ru(MeIm)2Cl]Cl [2.121(3) and 2.131(3) ].
[20]
Selected bond lengths and angles in the chlorido complexes
1b and 1c are also listed in Table 1, along with those in their
analogues 2b and 2c bearing 1-methylimidazole as the leaving
group. Overall, substitution of the chlorido ligands by 1-
methylimidazole resulted in slightly shorter distances between
the metal center and the S,O-donor atoms, indicating a higher
stability of the attached ligand scaffold. Both pairs of com-
plexes show differences in the Mleaving group bond lengths
[1b : 2.4357 , 2b : 2.1011 ; 1c : 2.4222 , 2c : 2.0984 ] due to
the different donor atoms. Nevertheless, the MCl and MN
bond lengths in the investigated complexes are in the same
range as those in the RuII complex RM175 published by Sadler
and co-workers.[21] An envelope conformation of the five-mem-
bered coordination cycle is apparent in both forms of the OsII
and RhIII complexes, but the torsion angle (O-M-S-C) is less pro-
Scheme 1. Overview of synthesized compounds 1a–d and 2a–d. i) [(p-cym)/
(Cp*)MCl2]2, NaOMe, methanol abs. ii) [(p-cym)/(Cp*)M(MeIm)2Cl]Cl, NaOMe,
methanol abs. , NaPF6.
Figure 2. Crystal structures of 1b and 1c with ellipsoids drawn at the 50%
probability level.
Figure 3. Crystal structures of 2b and 2c with ellipsoids drawn at the 50%
probability level (PF6
 counter ion omitted for clarity).
Table 1. Selected bond lengths and angles of OsII and RhIII compounds
1b, 2b, 1c, and 2c.
Compound 1b 2b 1c 2c
MS [] 2.3775 2.3652 2.3637 2.3399
MO [] 2.0864 2.0754 2.0924 2.0731
MCl/N [] 2.4357 2.1011 2.4222 2.0984
C=S [] 1.7035 1.7082 1.7032 1.7102
CO [] 1.3172 1.3185 1.3091 1.3130
p-plane centroid distance [] 1.6619 1.6684 1.7738 1.7692
ring slippage [] 0.039 0.035 0.031 0.033
O-M-S-C [8] 10.69 4.92 9.95 2.53
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nounced in complexes 2b and 2c (4.928 and 2.538, respective-
ly) compared to their chlorido counterparts 1b and 1c (10.698
and 9.958, respectively), which might be attributed to both the
increased steric demand of the 1-methylimidazole ligand and
the different donor properties. As expected, slightly shorter p-
plane–centroid distances were found for h6-coordinating moi-
eties compared to the h5-coordinative bond between the Cp*
ligand and the RhIII or IrIII metal centers.
Stability investigations by ESI-MS
The behavior of metal complexes in aqueous media is an im-
portant characteristic, since the MCl bond is prone to hydrol-
ysis. Aquation is believed to be an important step in the mode
of action of this compound class, because the comparatively
more reactive aqua complex is assumed to interact with bio-
logical targets. Therefore, the stability in aqueous solution was
investigated for all of the synthesized organometallics bearing
either chlorido (1a–d) or 1-methylimidazole (2a–d) leaving
groups. Samples were prepared according to the procedure
described in the Experimental Section and examined after 1, 3,
6, 24, and 48 h of incubation at 37 8C. A general tendency to-
wards increased stability of complexes bearing the 1-methyl-
imidazole leaving group could be discerned among the investi-
gated metal complexes. Overall, immediate cleavage of the
chlorido group was observed for 1a–d, yielding the respective
[MCl]+ species. Osmium complexes 1b and 2b proved to be
the most stable in the tested series. Besides the characteristic
peak of [1bCl]+ (m/z 467.040.02, mex 467.07), the spectrum
of compound 2b showed an additional species with the leav-
ing group 1-methylimidazole still coordinated to the metal
center, that is, [2b]+ (m/z 549.090.02, mex 549.12). RuII com-
plexes 1a and 2a behaved similarly to the respective osmium
compounds 1b and 2b. In accordance with its osmium equiva-
lent 2b, ruthenium complex 2a showed a corresponding peak
representing the species with the leaving group bound to the
metal center during the first 6 h of incubation, that is, [2a]+
(m/z 459.040.02, mex 459.07), besides the peak pertaining to
the complex without its leaving group [2aMeIm]+ (m/z
377.010.02, mex 377.02). In contrast to the abovementioned
occurrence of an additional peak with the azole leaving group
attached to the metal center, no such peak was detected in
the mass spectra of the corresponding IrIII and RhIII compounds
besides the characteristic [Mleaving group]+ peaks (1c, 2c :
m/z 379.010.01, mex 379.02; 1d, 2d : m/z 469.050.02, mex
469.08). Overall, replacement of the labile chlorido ligand by
methylimidazole as an N-donor improved the stability of the
organometallic complex in aqueous solution, and especially
the RuII and OsII compounds seemed to be more stable under
the applied conditions.
Stability of complex 1c and formation equilibrium processes
Due to the different behavior observed in the ESI-MS stability
experiments, complex formation equilibrium processes of 1c
were studied in aqueous solution by the combined use of pH-
potentiometric, 1H NMR, and UV/Vis titrations in the absence
and presence of chloride ions and compared to the reported
data for the ruthenium analogue 1a.[23] The stoichiometry and
stability constants of the formed complexes giving the best fits
to the experimental data are listed in Table 2.
As chloride ions may possibly coordinate by partly replacing
the aqua ligands, the stability constants determined in a chlor-
ide-containing medium are regarded as conditional stability
constants and are valid only under the given conditions. Thio-
maltol can undergo oxidation in the alkaline pH range, and
thus anaerobic conditions were applied. According to pH-po-
tentiometric titration curves recorded at a 1:1 metal-to-ligand
ratio, proton displacement by the metal ion was complete at
a starting pH of around 2 in both experimental setups (I=
0.2m KCl or KNO3). Additional signals belonging neither to the
methyl protons of the unbound RhIII-Cp* fragment nor to the
ligand were detected at this pH by 1H NMR spectroscopy (Fig-
ure S9). These findings hampered determination of the stability
constant of the mono-ligand complex [RhCp*(L)(H2O)]
+ denot-
ed as [ML]. Therefore, UV/Vis spectrophotometry was applied
Table 2. Proton dissociation constant (pKa) of thiomaltol and overall, stepwise, and derived stability constants of its RhCp* complexes in chloride-free and
chloride-containing aqueous solutions determined by various methods, and H2O/Cl
 exchange constant (logK) for the [ML(H2O)]
+ complex {T=25 8C; I=
0.20m}.[a]
Constant Equilibrium 0.2m KNO3 0.2m KCl Method Notes
pKa (HL) HLQH+L 8.16(1) 8.06(1) pH-metry –
logK [ML] M+LQ[ML] >15.0 >15.0 UV/Vis (pH 0.72) estimated;= logß [ML]
logK [ML2H] [ML]+HLQ[ML2H] 4.9(1) 4.9(1) 1H NMR at pH 2.70 (KNO3); pH 3.85 (KCl)
logß [ML2H] M+2L+HQ[ML2H] >28.1 >28.0 various methods,
calculated
= logK [ML2H] + logK [ML] + pKa (HL)
pKa [ML2H] [ML2H]Q[ML2]+H 6.37(1) 6.33(4) 1H NMR –
6.4 6.2 pH-metry, calculated = logß [ML2H]  logß [ML2]
logß [ML2] M+2LQ[ML2] >21.7 >21.7 1H NMR, calculated = logß [ML2H]  pKa [ML2H]
>21.6(1) >21.8(1) pH-metry logß [ML] and logß [ML2H]
kept constant during the data evaluation
logK (H2O/Cl
) [ML(H2O)]
+ +ClQ[ML(Cl)]+H2O 0.95(1) 0.95(1) UV/Vis determined at pH 3.1
[a] Charges of the complexes are omitted for simplicity. Standard deviations (SD) are given in parentheses. Hydrolysis products of the organometallic
cation: logß [M2H2]=11.12, logß [M2H3]=19.01 at I=0.20m (KCl) and logß [M2H2]=8.53, logß [M2H3]=14.26 at I=0.20m (KNO3) taken from
the literature.[22]
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under more dilute conditions in the pH range 0.7–2.0 to force
dissociation of the complex. These spectra were found to be
identical (Figure S10), suggesting that the complex is still
intact in this pH range due to its outstandingly high stability,
similar to that of 1a.[23] Therefore, only a threshold limit could
be estimated for logb [ML] (Table 2). It is noteworthy that thio-
maltol forms significantly more stable complexes than analo-
gous (O,O)-hydroxypyrones, with logb values at least six orders
of magnitude higher.[21] Deprotonation of [RhCp*(L)(H2O)]
+ was
observed at pH>6, leading to precipitation of the product
(Figure 4).
The speciation in the RhCp*-thiomaltol system was found to
be different and more complicated in the presence of excess
ligand compared to the complexes of other types of bidentate
O,O-, O,N-, or N,N-ligands,[21–23] since the latter form exclusively
mono-ligand [ML] and [ML(OH)] complexes in aqueous solu-
tion. Careful analysis of the 1H NMR spectra recorded at various
metal-to-ligand ratios revealed the formation of bis-ligand
complexes of thiomaltol, besides the respective species [ML],
in which an additional thiomaltol ligand coordinates in a mono-
dentate fashion through its thio group (Scheme S1 and Figur-
es S11 and S12). Similar mixed coordination modes have been
reported for the RuII(p-cym) complexes of hydroxypyr-
(idin)ones.[23,24] The Cl/H2O exchange process was found to be
fast (Figure S13) and the obtained logK (H2O/Cl
) of 0.95 is
similar to those obtained for the RhCp* complexes of hydroxy-
pyr(idin)ones with an O,O-donor set (maltol : 1.17, allomaltol :
1.38,[22] deferiprone: 0.78,[25] and the RuII(p-cym) complex of thi-
oallomaltol: 0.71[23]), although it is considerably lower than the
values obtained for the biologically inactive complexes with
N,N-donor ligands 2,2’-bipyridine or ethylenediamine.[26]
Investigation of amino acid interaction by ESI-MS
In order to acquire more detailed information about the be-
havior of the synthesized complexes in biological media and
with regard to possible binding partners on entering the body
by intravenous administration, their reactivity towards the
amino acids glycine, l-histidine, and l-cysteine was tested. As
previously demonstrated in the literature,[13] in the presence of
amino acids or proteins such as ubiquitin, ruthenium(II) (thio)-
pyr(id)one compounds react with these molecules by cleavage
of the ligand scaffold, forming adducts of the form [(p-cym)
Ru+Ub/amino acid]+ . Whereas this effect is observed to
a great extent within the first few hours in the case of O,O-co-
ordinating ligands, the thiomaltolato complex was found to
persist for longer in the presence of the tested biomolecules.
Only after 24 h of incubation were the first biomolecule ad-
ducts and ligand release detected. To investigate the change
in stability imparted by the introduction of the 1-methyl-
imidazole leaving group, the two ruthenium compounds 1a
and 2a as well as the two rhodium complexes 1c and 2c were
chosen. Samples were prepared as described in the Experimen-
tal Section. Investigation of compound 1a revealed the forma-
tion of l-histidine (His) adducts after 6 h [1aCl+His]+ (m/z
532.100.02, mex 532.08). After 24 h of incubation, the thio-
maltol ligand was cleaved, giving rise to His- as well as l-cys-
teine (Cys)-containing adducts [(p-cym)Ru+His]+ (m/z 390.05
0.02, mex 390.08) and [(p-cym)Ru+Cys]
+ (m/z 356.010.02, mex
356.03). In general, the formation of l-histidine adducts seems
to be favored in the recorded spectra of 1a compared to l-cys-
teine coordination. In the spectrum recorded after 48 h,
a small amount of a ligand-bearing dimeric species [(p-
cym)2Ru2L1(OH)2(CH3OH)]
+ (m/z 678.10, mex 678.06) was de-
tected. In the case of 2a, increased stability compared to its
chlorido analogue can be inferred since the intact compound
[2aMeIm]+ was detected throughout the whole incubation
period. During the first 6 h of incubation, only two species
could be observed, namely [2aMeIm]+ (m/z 377.01, mex
377.02) and [2a]+ (m/z 459.040.02, mex 459.07). After 6 h,
the adduct [2aMeIm+His]+ (m/z 532.100.02, mex 532.08)
was found besides the two intact compound species described
above. Cleavage of the ligand had only occurred to a very
small extent after 24 h, leading to the species [(p-cym)Ru+
His]+ and [(p-cym)Ru+Cys]+ . Equal amounts of three species
were found after 48 h of incubation: [2aMeIm]+ (m/z 377.10,
mex 377.02), [(p-cym)Ru+His]
+ (m/z 390.050.02, mex 390.08),
and the ligand-bearing dimeric species [(p-cym)2Ru2
L1(OH)2(CH3OH)]
+ (m/z 678.10, mex 678.06). Enhanced stability
was also observed for the 1-methylimidazole-bearing organo-
rhodium complex 2c compared to the chlorido analogue 1c.
After just 3 h, 1c had started to form the [(Cp*)Rh+Cys]
adduct (m/z 358.010.02, mex 358.03), which became the pre-
dominant species at the end of the incubation period along
with [(Cp*)Rh+His]+ (m/z 392.050.02, mex 392.08). In con-
trast, 2c resisted ligand cleavage induced by amino acid bind-
ing for more than 24 h, and this was found only to a very
small degree thereafter. Therefore, substitution of the labile
chlorido group by 1-methylimidazole is a successful strategy to
increase the stability of the organometallic thiomaltol com-
plexes, enabling them to reach tumor tissue intact, in contrast
to the respective chlorido analogues or complexes with com-
parable O,O-coordinating ligands.
Figure 4. UV/Vis spectra recorded for the [RhCp*(H2O)3]
2+–thiomaltol (1:1)
system in the pH range 2.0–11.4. The inset shows the pH-dependence of ab-
sorbance values at 264 nm at pH>2 () and in the pH range 0.7–2.0 using
individual samples (+) {cL=48 mm ; cM=48 mm ; T=25 8C; I=0.20m (KCl/HCl) ;
l=2 cm}.
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pH-Dependent cleavage of the 1-methylimidazole leaving
group
Given the indication of a characteristically lowered pH level by
0.5 to 1 units in tumor tissues, depending on the size and
tumor type,[14,27] the behavior of the synthesized compounds
under pH variation was of great interest. Thus, pH-dependent
stability studies of complexes 2a–d were conducted by
1H NMR measurements in order to gain knowledge about the
formation of the respective aqua species upon pH-induced
cleavage of the coordinated azole ligand. In general, all four
complexes behaved very similarly on varying the pH. Com-
pounds 2a–d were dissolved in D2O, and pD values were ad-
justed by the addition of DCl and NaOD over a wide pH range
(2.5–12). The obtained pD values were converted to the corre-
sponding pH values according to Equation (2), as described in
the Experimental Section. The shifts of the 1-methylimidazole
and arene signals were monitored, and in the case of com-
pounds 2a and 2b the formation of the aqua species led to
an additional set of signals corresponding to the aromatic
cymene protons. The intact complexes exhibited four signals
corresponding to the four aromatic protons, whereas the re-
placement of the leaving group by a water molecule led to
the appearance of two broad peaks in the aromatic region. An-
other indication of the formation of the aqua species was pro-
vided by the emergence of peaks attributable to the free 1-
methylimidazole ligand. These signals were also used to assess
the behavior of compounds 2c and 2d under pH variation.
Formation of the respective aqua species could be observed
starting at pH 6, until it became the predominant species at
values around pH 3.5 (Figure 5). Complexes 2a–d showed very
high stabilities under alkaline conditions and no degradation
products could be detected at up to pH 11 (Table S15 in the
Supporting Information). Based on these findings, it can be as-
sumed that under the hypoxic conditions of the tumor micro-
environment, the leaving group may be partly cleaved to form
the corresponding more reactive aqua complex.
Cytotoxicity
Analogous maltol and allomaltol RhIII Cp* complexes were re-
cently reported to show moderate anticancer activity against
the human cancer cell lines CH1/PA-1 (ovarian teratocarcino-
ma), SW480 (colon carcinoma), and A549 (non-small cell lung
carcinoma).[22] The cytotoxicity of complex 1a in CH1/PA-1 and
SW480 cells has been reported previously, whereas data per-
taining to A549 cells have been determined for the first time
here. The thiomaltolato complexes 1a–2d and the respective
free thiomaltol ligand L1 were tested against the same human
cancer cell lines. In general, all complexes showed IC50 values
in the low micromolar to submicromolar range (Table 3), and
are therefore far more potent than their pyrone analogues.[19]
Surprisingly, even the free ligand L1 proved to be highly cyto-
toxic against the tested cell lines and overall it seems that thio-
maltol is the activity-determining factor for this class of com-
plexes. In general, the chlorido complexes 1b–d showed simi-
lar activities, but were found to be more active than 1a. The
two different monodentate leaving groups have only a margin-
al impact on the activity because the supposed activation of
the organometallics requires release of the leaving group. In
contrast to the chlorido complexes 1a–d, a small effect of the
metal center on the cytotoxicity was observed for complexes
2a–d. In particular, the RuII and RhIII representatives 2a and 2c
were found to be more active than their chlorido counterparts
by factors of up to 3.7, depending on the cell line. The P-glyco-
protein (P-gp) expressing cell line SW480 proved to be as sen-
sitive to most of the complexes as the broadly chemosensitive
CH1/PA-1 cell line, whereas IC50 values against the more che-
moresistant cell line A549 were up to ten-fold higher. This fea-
ture of the investigated set of compounds is in sharp contrast
to the well-established PtII complexes, such as cisplatin, which
is about 20 times less potent against SW480 than against CH1
cells (data taken from the literature).[28] As SW480 cells express
low levels of ABCB1 (P-gp)[29] and A549 cells overexpress multi-
ple transporters of the ABC family (e.g. , ABCC2 (MRP2), ABCC4
(MRP4), ABCC5 (MRP5)),[30–32] investigations concerning the in-
fluence of such transporters on the activity of organometallic
complexes will be a subject of future research.
Topoisomerase IIa inhibition
Topoisomerase IIa is an essential nuclear enzyme involved in
almost every aspect of DNA functionality : replication, transcrip-
tion, recombination, and chromosome condensation. Topoiso-
merase IIa is a primary target for active anticancer drugs. Sev-
eral studies have revealed that clinically active drugs that
target topoisomerase IIa generate enzyme-mediated DNA
damage.[35–37] The compounds reported here were studied by
a DNA relaxation assay for their topoisomerase IIa inhibitory
properties. Complexes 1a–d and 2b–d displayed inhibitory ca-
pacity at a concentration of 10 mm. In addition, the RuII com-
plex 2a proved to be a potent enzyme inhibitor at just 2.5 mm,
which is in contrast to the comparatively high IC50 values of 2a
within the series of 1-methylimidazole-substituted compounds.
In comparison, the corresponding ligand L1 did not inhibit the
Figure 5. 1H NMR spectra of compound 2a in D2O at different pH values
(4.8–9.8).
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enzyme appreciably at the applied concentrations. Figures 6
and 7 show that the tested compounds did not act as topoiso-
merase poisons, since the linear DNA band was only present in
the positive control, whereby the action of the poison gener-
ates a high level of TopoII–DNA covalent complexes, resulting
in the accumulation of DNA double-strand breaks. It is more
likely that the tested complexes act as catalytic inhibitors,
blocking the ATP-binding site of the enzyme, preventing bind-
ing of the enzyme to DNA or the release of DNA.[36] Similar be-
havior in the presence of topoisomerase IIa was observed for
RuII and RhIII complexes of comparable architecture, with inhib-
itory effects on topoisomerase IIa starting at concentrations
between 5 and 20 mm.[38,39]
Cell cycle and ROS studies
Since the tested compounds exhibited properties of topoiso-
merase IIa catalytic inhibitors and may disrupt some essential
processes, such as transcription and replication, we examined
the changes in cell cycle distribution by flow cytometry using
propidium iodide staining. As illustrated in Figure 8, the effects
on SW480 cells after 12 h of treatment were pronounced: the
highest S-phase accumulations were seen for ruthenium(II) and
iridium(III) complexes (2a and 2d), with an increase to around
45% at a concentration of 20 mm. Detailed cell cycle distribu-
tion data are summarized in Table S16.
Furthermore, we investigated whether the thiomaltol-based
organometallic complexes could alter the levels of reactive
oxygen species (ROS) in cancer cells (Figure 9) by means of
a 2’,7’-dichlorofluorescein diacetate (DCF-DA) assay. It has been
reported by Sadler and co-workers that certain organorutheni-
um complexes are able to catalytically reduce GSH levels, lead-
ing to an increase of ROS formation.[40,41] Our complexes were
studied with regard to their potential to raise cellular ROS
levels, and the obtained data indicated slight increases in ROS
levels for the rhodium(III) 1-methylimidazole-substituted com-
plex 2c by a factor of 2.7 and for the iridium(III) 1-methylimida-
zole-substituted complex 2d by a factor of 1.5, but no discerni-
ble effect for the other tested substances. Table S17 shows the
detailed ROS generation data. Based on these findings, the for-
mation of ROS does not convincingly contribute to the cyto-
toxicity of thiopyrone-based organometallics.
In summary, these results suggest that topoisomerase IIa
may be a target for organometallic thiomaltol-based com-
plexes, whereas the free ligand is devoid of enzyme inhibitory
Table 3. Inhibition of cancer cell growth by the tested substances in
three human cancer cell lines; 50% inhibitory concentrations (means 
standard deviations), obtained by MTT assay (exposure time: 96 h).
IC50 value SD
Compound M A549 CH1/PA-1 SW480
1a RuII 124 31 111
1b OsII 4.10.3 2.00.2 2.00.2
1c RhIII 5.90.8 1.00.1 1.00.1
1d IrIII 5.81.7 0.570.03 0.70.1
2a RuII 7.11.6 2.60.5 3.00.2
2b OsII 6.60.4 3.00.4 3.40.7
2c RhIII 2.60.6 0.90.2 0.480.03
2d IrIII 3.40.8 0.60.1 0.670.04
L1 – 1.30.8 0.520.04 0.550.31
cisplatin[a] PtII 1.30.4 0.160.03 3.50.3
NKP-1339[b] RuIII 15611 506 629
[a] See ref. [33] . [b] See ref. [34] .
Figure 6. Topoisomerase IIa-inhibitory capacities of complexes 1a–d deter-
mined by the plasmid DNA relaxation assay. Supercoiled and linear DNA
used as references (lanes 1 and 2, respectively) ; relaxed DNA bands (lane 3)
indicating intact enzyme activity ; DMSO control corresponding to maximum
content in test compound solutions (lane 4) ; linear DNA band induced by
0.8 mm etoposide (positive control, lane 5). Lanes 6–13 display the reaction
of topoisomerase IIa with supercoiled DNA in the presence of the test com-
pounds. The top gel (A) was post-stained and the bottom gel (B) was pre-
stained with 0.7 mgmL1 ethidium bromide.
Figure 7. Topoisomerase IIa-inhibitory capacities of complexes 2a–d and
ligand L1 determined by the plasmid DNA relaxation assay. Supercoiled and
linear DNA used as references (lanes 1 and 2, respectively); relaxed DNA
bands (lane 3) indicating intact enzyme activity ; linear DNA band induced
by 0.8 mm etoposide (positive control, lane 4). Lanes 5–14 display the reac-
tion of topoisomerase IIa with supercoiled DNA in the presence of the test
compounds. The top gel (A) was post-stained and the bottom gel (B) was
pre-stained with 0.7 mgmL1 ethidium bromide.
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properties at the same concentration. None of these com-
pounds act as topoisomerase IIa poisons. Cell cycle distribu-
tion analyses revealed a moderate increase of the S-phase frac-
tion upon exposure to the organometallics, consistent with in-
hibition of this key enzyme. In addition, ROS production ap-
pears unlikely to play a central role in the cellular response to
treatment with these metal complexes. A general overview of
cytotoxicity, enzyme inhibition, cell cycle perturbations, and
ROS activation of thiomaltol-based complexes suggests that
metal coordination has a distinct impact on the biological ac-
tivity.
Conclusions
Thiomaltol-based organometallics are characterized by in-
creased stability compared to their pyrone analogues, making
them more suitable for metallodrug development. In this work,
thiomaltol-bearing complexes with RuII, OsII, RhIII, and IrIII, bear-
ing either 1-methylimidazole or chloride as leaving group,
have been synthesized, and the effects of different metal cen-
ters and leaving groups on the physicochemical and biological
properties have been investigated. The acquired data implied
that the introduction of 1-methylimidazole as a leaving group
substantially increases the stability in aqueous solution and
shields the complex from coordination of biomolecules that
would lead to ligand release. This modification may allow accu-
mulation of the intact complexes and controlled activation at
the lower pH values within tumor tissues. The synthesized sub-
stances were tested against three different human cancer cell
lines with regard to their anticancer potential, and promising
IC50 values in the low mm to sub-mm range were observed.
Whereas the complexes proved to be good topoisomerase IIa
inhibitors, the thiomaltol ligand alone proved to be inactive
and the tested substances were evidently not poisons to the
enzyme. The complexes induce changes in the cell cycle, such
that an accumulation of cells in the S-phase was observed. Ac-
cording to these findings, topoisomerase IIa might be a possi-
ble target of organometallic thiopyrones. Based on the data
presented herein, thiomaltol-based organometallic complexes
can be regarded as promising candidates for the further devel-
opment of anticancer agents with topoisomerase IIa inhibitory
properties.
Figure 8. Concentration-dependent impact of thiomaltol-based organome-
tallic complexes 1a–d and 2a–d and the corresponding ligand L1 at a con-
centration of 20 mm on the cell-cycle distribution of SW480 cells after 12 h of
continuous exposure.
Figure 9. Generation of ROS as indicated by DCF-DA microplate assay using complexes: A) 1a–d, B) 2a–d and L1. Mean  standard deviation is plotted for
three replicates at each concentration. The relative fluorescence unit (RFU) for all samples was normalized to the RFU of stained untreated control (indicated
by a dashed line).
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Experimental Section
Materials
The dimeric metal precursors [Ru(p-cym)Cl2]2, [Os(p-cym)Cl2]2,
[Rh(Cp*)Cl2]2, and [Ir(Cp*)Cl2]2 were prepared according to literature
procedures.[16, 42,43] The solvents used were purchased from com-
mercial sources and distilled prior to use. Methanol (HPLC grade,
Fisher) and Millipore water (MilliQ H2O; 18.2 MW; Synergy 185 UV
Ultrapure Water System, Millipore) were used for mass spectromet-
ric investigations and titrations. 3-Hydroxy-2-methyl-4H-pyran-4-
one (99.0%, Aldrich), Lawesson’s reagent (99%, Acros), osmi-
um(VIII) tetroxide (Johnson Matthey), hydrazine dihydrochloride
(>98%, Aldrich), hydrochloric acid (37%, Acros), a-terpinene (90%,
Acros), iridium(III) chloride (Johnson Matthey), 1,2,3,4,5-pentame-
thylcyclopentadiene (95%, Aldrich), ruthenium(III) chloride hydrate
(Johnson Matthey), rhodium(III) chloride hydrate (Johnson Mat-
they), 1-methylimidazole (99%, Aldrich), sodium methoxide (ca.
95%, Fluka), sodium hexafluorophosphate (98%, Aldrich), glycine
(Merck), l-cysteine (Fluka), and l-histidine (Merck) were purchased
and used as received. KCl, KNO3, AgNO3, HCl, HNO3, KOH, and 4,4-
dimethyl-4-silapentane-1-sulfonic acid (DSS) were purchased from
Sigma–Aldrich in puriss quality. NMR spectra were recorded at
25 8C on a Bruker Avance IIITM 500 MHz FT-NMR spectrometer.
1H NMR spectra were measured at 500.10 MHz and 13C NMR spec-
tra at 125.75 MHz from solutions in deuterated dimethyl sulfoxide,
methanol, or chloroform. DCl (35%) and NaOD (4%) were used for
the stability investigation of complexes at varying pH values. CHNS
elemental analyses were carried out on a Eurovector EA3000 ele-
mental analyzer in the microanalytical laboratory of the University
of Vienna.
General procedures
General procedure for the synthesis of OsII/RuII cymene and IrIII/
RhIII Cp* chlorido complexes : Ligand L1 (1 equiv) and sodium
methoxide (1.1 equiv) were dissolved in absolute methanol and
the solution was stirred for 15 min under inert conditions. The
yellow solution was then transferred to a Schlenk flask containing
the respective dimer (0.45 equiv), whereupon it underwent an im-
mediate color change. The mixture was stirred under argon atmos-
phere at 40 8C for 1.5 h. Thereafter, the solvent was evaporated
under reduced pressure and the residue was redissolved in di-
chloromethane. Filtration allowed the removal of reaction by-prod-
ucts, and the filtrate was concentrated in vacuo. Precipitation from
n-hexane afforded the pure product in good to excellent yields
(63–92%).
General procedure for the synthesis of OsII/RuII cymene and IrIII/
RhIII Cp* 1-methylimidazole complexes : The ligand L1 (1 equiv)
and sodium methoxide (1.1 equiv) were dissolved in absolute
methanol and the solution was stirred for 15 min under inert con-
ditions. The yellow solution was then transferred to a Schlenk flask
containing the respective precursor complex (0.9 equiv), where-
upon it underwent an immediate color change. The mixture was
stirred under argon atmosphere at 40 8C for 4–48 h, depending on
the relevant precursor metal complex. In order to separate the de-
sired product from uncharged side products, sodium hexafluoro-
phosphate was added and the resulting mixture was stirred for
a further 1 h at room temperature. Thereafter, the solvent was
evaporated under reduced pressure and the residue was taken up
in dichloromethane. Filtration allowed the removal of reaction by-
products and the filtrate was concentrated in vacuo. Precipitation
from dichloromethane/diethyl ether afforded the pure product in
low to moderate yields (32–52%).
[Chlorido(2-methyl-3-(oxo-kO)-pyran-4(1H)-thionato-kS)(h6-p-
cymene)osmium(II)] (1b): The reaction was performed according
to the general procedure for chlorido complexes using L1 (60 mg,
0.42 mmol, 1 equiv), sodium methoxide (25 mg, 0.46 mmol,
1.1 equiv), and [(h6-p-cym)OsIICl2]2 (150 mg, 0.19 mmol, 0.45 equiv).
The product was isolated as a red solid. Yield: 135 mg (71%).
1H NMR (500.10 MHz, CDCl3, 25 8C): d=1.28 (d,
3J(H,H)=7 Hz, 6H;
CH3,cym), 2.33 (s, 3H; CH3,cym), 2.51 (s, 3H; CH3), 2.67–2.75 (m, 1H;
CHcym), 5.62 (br s, 2H; CHAr), 5.82 (br s, 2H; CHAr), 7.26 (d,
3J(H,H)=
5 Hz, 1H; CH-5), 7.43 ppm (d, 3J(H,H)=5 Hz, 1H; CH-6); 13C NMR
(125.75 MHz, CDCl3, 25 8C): d=15.4 (CH3), 18.5 (CH3,cym), 22.4 & 22.9
(2CH3,cym), 31.4 (CHcym), 73.2 (CHAr), 75.0 (CHAr), 90.3 (Cq,Ar), 90.8
(Cq,Ar), 120.7 (CH-5), 144.6 (CH-6), 153.5 (Cq-2), 168.5 (Cq-3),
181.9 ppm (Cq-4); elemental analysis calcd (%) for C16H19ClO2OsS: C
38.35, H 3.82, S 6.40; found: C 38.48, H 3.98, S 6.30.
[Chlorido(2-methyl-3-(oxo-kO)-pyran-4(1H)-thionato-kS)(h5-
1,2,3,4,5-pentamethylcyclopentadienyl)rhodium(III)] (1c): The re-
action was performed according to the general procedure for
chlorido complexes using L1 (78 mg, 0.55 mmol, 1 equiv), sodium
methoxide (32 mg, 0.60 mmol, 1.1 equiv), and [(h5-Cp*)RhIIICl2]2
(150 mg, 0.24 mmol, 0.45 equiv). The product was isolated as a red
solid. Yield: 189 mg (95%). 1H NMR (500.10 MHz, CDCl3, 25 8C): d=
1.75 (s, 15H; CH3,Cp*), 2.45 (s, 3H; CH3), 7.17 (d,
3J(H,H)=5 Hz, 1H;
CH-5), 7.45 ppm (d, 3J(H,H)=5 Hz, 1H; CH-6); 13C NMR (125.75 MHz,
CDCl3, 25 8C): d=9.0 (CH3,Cp*), 15.5 (CH3), 94.0 (d,
1J(Rh,C)=10 Hz;
CCp*), 120.9 (CH-5), 143.7 (CH-6), 153.7 (Cq-2), 165.5 (Cq-3),
180.0 ppm (Cq-4); elemental analysis calcd (%) for
C16H19ClO2RhS·0.5H2O: C 45.46, H 4.77, S 7.59; found: C 45.35, H
4.92, S 7.70.
[Chlorido(2-methyl-3-(oxo-kO)-pyran-4(1H)-thionato-kS)(h5-
1,2,3,4,5-pentamethylcyclopentadienyl)iridium(III)] (1d): The re-
action was performed according to the general protocol for chlori-
do complexes using L1 (60 mg, 0.42 mmol, 1 equiv), sodium meth-
oxide (25 mg, 0.46 mmol, 1.1 equiv), and [(h5-Cp*)IrIIICl2]2 (150 mg,
0.19 mmol, 0.45 equiv). The product was isolated as a red solid.
Yield: 165 mg (86%). 1H NMR (500.10 MHz, CDCl3, 25 8C): d=1.78
(s, 15H; CH3,Cp*), 2.52 (s, 3H; CH3), 7.18 (d,
3J(H,H)=5 Hz, 1H; CH-5),
7.45 ppm (d, 3J(H,H)=5 Hz, 1H; CH-6); 13C NMR (125.75 MHz,
CDCl3, 25 8C): d=8.9 (CH3,Cp*), 15.5 (CH3), 86.2 (d,
1J(Ir,C)=10 Hz;
CCp*), 121.8 (CH-5), 143.7 (CH-6), 154.2 (Cq-2), 167.7 (Cq-3),
179.4 ppm (Cq-4); elemental analysis calcd (%) for
C16H20ClIrO2S·H2O: C 36.81, H 4.25, S 6.14; found: C 36.72, H 3.98, S
6.43.
[(1-Methylimidazole-kN3)(2-methyl-3-(oxo-kO)-pyran-4(1H)-thio-
nato-kS)(h6-p-cymene)ruthenium(II)] hexafluorophosphate (2a):
The reaction was performed according to the general procedure
for the synthesis of metal complexes with 1-methylimidazole as
leaving group, using ligand L1 (51 mg, 0.354 mmol, 1 equiv),
sodium methoxide (21 mg, 0.390 mmol, 1.1 equiv), and [(h6-p-cym)
RuII(MeIm)2Cl]Cl (150 mg, 0.319 mmol, 0.9 equiv). The mixture was
stirred at 40 8C for 40 h, affording the desired product after work-
up as orange crystals. Yield: 79 mg (41%). 1H NMR (500.10 MHz,
[D4]methanol, 25 8C): d=1.25–1.28 (m, 6H; CH3,cym), 2.07 (s, 3H;
CH3,cym), 2.50 (s, 3H; CH3), 2.67–2.76 (m, 1H; CHcym), 3.72 (s, 3H;
CH3,MeIm), 5.46–5.55 (m, 2H; CHAr), 5.69–5.75 (m, 2H; CHAr), 6.95 (s,
1H; CHMeIm), 7.07 (s, 1H; CHMeIm), 7.28 (d,
3J(H,H)=5 Hz, 1H; CH-5),
7.70 (s, 1H; CHMeIm), 7.75 ppm (d,
3J(H,H)=5 Hz, 1H; CH-6);
13C NMR (125.75 MHz, [D4]methanol, 25 8C): d=13.7 (CH3), 16.8
(CH3,cym), 21.0 & 21.7 (2CH3,cym), 30.9 (CHcym), 33.2 (CH3,MeIm), 81.1 &
82.6 (2CHAr), 83.5 & 84.6 (2CHAr), 100.2 (Cq,Ar), 103.0 (Cq,Ar), 119.8
(CH-5), 121.6 (CHMeIm), 129.5 (CHMeIm), 139.8 (CHMeIm), 145.9 (C-6),
154.1 (Cq-2), 164.9 (Cq-3), 180.1 ppm (Cq-4); elemental analysis calcd
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(%) for C20H25F6N2O2PRuS: C 39.80, H 4.18, N 4.64, S 5.31; found: C
39.81, H 4.14, N 4.67, S 5.23.
[(1-Methylimidazole-kN3)(2-methyl-3-(oxo-kO)-pyran-4(1H)-thio-
nato-kS)(h6-p-cymene)osmium(II)] hexafluorophosphate (2b):
The reaction was performed according to the general procedure
for the synthesis of metal complexes with 1-methylimidazole as
leaving group, using ligand L1 (43 mg, 0.298 mmol, 1 equiv),
sodium methoxide (18 mg, 0.328 mmol, 1.1 equiv), and [(h6-p-cym)
OsII(MeIm)2Cl]Cl (150 mg, 0.268 mmol, 0.9 equiv). The mixture was
stirred at 40 8C for 48 h affording the desired product after work-
up as red-brown crystals. Yield: 75 mg (40%). 1H NMR (500.10 MHz,
[D4]methanol, 25 8C): d=1.22–1.28 (m, 6H; CH3,cym), 2.13 (s, 3H;
CH3,cym), 2.53 (s, 3H; CH3), 2.57–2.66 (m, 1H; CHcym), 3.74 (s, 3H;
CH3,MeIm), 5.68–5.77 (m, 2H; CHAr), 5.85–5.94 (m, 2H; CHAr), 6.94 (s,
1H; CHMeIm), 7.04 (s, 1H; CHMeIm), 7.36 (d,
3J(H,H)=5 Hz, 1H; CH-5),
7.72 (s, 1H; CHMeIm), 7.75 ppm (d,
3J(H,H)=5 Hz, 1H; CH-6);
13C NMR (125.75 MHz, [D4]methanol, 25 8C): d=13.8 (CH3), 16.7
(CH3,cym), 21.3 & 22.1 (2CH3,cym), 31.1 (CHcym), 33.2 (CH3,MeIm), 71.7 &
73.3 (2CHAr), 74.9 & 76.2 (2CHAr), 92.0 (Cq,Ar), 93.3 (Cq,Ar), 120.2 (CH-
5), 121.4 (CHMeIm), 128.9 (CHMeIm), 139.5 (CHMeIm), 146.7 (CH-6), 154.6
(Cq-2), 167.5 (Cq-3), 180.7 ppm (Cq-4); elemental analysis calcd (%)
for C20H25F6N2O2OsPS: C 34.68, H 3.64, N 4.04, S 4.63; found: C
34.69, H 3.56, N 4.02, S 4.54.
[(1-Methylimidazole-kN3)(2-methyl-3-(oxo-kO)-pyran-4(1H)-thio-
nato-kS)(h5-1,2,3,4,5-pentamethylcyclopentadienyl)rhodium(III)]
hexafluorophosphate (2c): The reaction was performed according
to the general procedure for the synthesis of metal complexes
with 1-methylimidazole as leaving group, using ligand L1 (50 mg,
0.352 mmol, 1 equiv), sodium methoxide (21 mg, 0.387 mmol,
1.1 equiv), and [(h5-Cp*)RhIII(MeIm)2Cl]Cl (150 mg, 0.317 mmol,
0.9 equiv). The mixture was stirred at 40 8C for 4 h, affording the
desired product after work-up as orange crystals. Yield: 100 mg
(52%). 1H NMR (500.10 MHz, [D4]methanol, 25 8C): d=1.70 (s, 15H;
CH3,Cp*), 2.53 (s, 3H; CH3), 3.77 (s, 3H; CH3,MeIm), 7.02 (br s, 1H;
CHMeIm), 7.17 (br s, 1H; CHMeIm), 7.27 (d,
3J(H,H)=5 Hz, 1H; CH-5),
7.79 ppm (br s, 2H; CHMeIm & CH-6);
13C NMR (125.75 MHz,
[D4]methanol, 25 8C): d=7.5 (CH3,Cp*), 13.7 (CH3), 33.5 (CH3,MeIm), 95.3
(d, 1J(Rh,C)=10 Hz; CCp*), 120.5 (CH-5), 122.1 (CHMeIm), 123.1
(CHMeIm), 129.1 (CHMeIm), 146.7 (CH-6), 154.8 (Cq-2), 164.8 (Cq-3),
179.3 ppm (Cq-4); elemental analysis calcd (%) for
C20H26F6N2O2PRhS: C 39.62, H 4.32, N 4.62, S 5.29; found: C 39.66, H
4.33, N 4.56, S 5.30.
[(1-Methylimidazole-kN3)(2-methyl-3-(oxo-kO)-pyran-4(1H)-thio-
nato-kS)(h5-1,2,3,4,5-pentamethylcyclopentadienyl)iridium(III)]
hexafluorophosphate (2d): The reaction was performed according
to the general procedure for the synthesis of metal complexes
with 1-methylimidazole as leaving group, using ligand L1 (42 mg,
0.296 mmol, 1 equiv), sodium methoxide (18 mg, 0.326 mmol,
1.1 equiv), and [(h6-Cp*)IrIII(MeIm)2Cl]Cl (150 mg, 0.267 mmol,
0.9 equiv). The mixture was stirred at 40 8C for 4 h, affording the
desired product after work-up as orange-brown crystals. Yield:
61 mg (32%). 1H NMR (500.10 MHz, [D4]methanol, 25 8C): d=1.72
(s, 15H; CH3,Cp*), 2.55 (s, 3H; CH3), 3.79 (s, 3H; CH3,MeIm), 7.00 (br s,
1H; CHMeIm), 7.15 (br s, 1H; CHMeIm), 7.31 (br s, 1H; CH-5), 7.78 ppm
(br s, 2H; CHMeIm & CH-6);
13C NMR (125.75 MHz, [D4]methanol,
25 8C): d=7.4 (CH3,Cp*), 13.7 (CH3), 33.4 (CH3,MeIm), 87.7 (d,
1J(Ir,C)=
10 Hz; CCp*), 121.3 (CH-5), 122.0 (CHMeIm), 123.3 (CHMeIm), 129.4
(CHMeIm), 146.1 (CH-6), 154.9 (Cq-2), 165.8 (Cq-3), 179.1 ppm (Cq-4);
elemental analysis calcd (%) for C20H26F6IrN2O2PS: C 34.53, H 3.77, N
4.03, S 4.61; found: C 34.19, H 3.65, N 3.98, S 4.67.
Single-crystal X-ray diffraction analysis
X-ray intensity data were measured on a Bruker D8 Venture diffrac-
tor equipped with a multilayer monochromator, an MoKa INCOATEC
microfocus sealed tube, and a Kryoflex II cooling device. Structures
were solved by direct methods and refined by full-matrix least-
squares techniques. Non-hydrogen atoms were refined with aniso-
tropic displacement parameters. Hydrogen atoms were inserted at
calculated positions and refined with riding coordinates. The fol-
lowing software was used: frame integration, Bruker SAINT soft-
ware package[44] using a narrow-frame algorithm; absorption cor-
rection, SADABS;[45] structure solution, SHELXS-2013;[46] refinement,
SHELXL-2013,[46] OLEX2,[47] and SHELXLE;[48] molecular diagrams,
OLEX2.[47] CCDC1486550 (1b), 1486549 (1c), 1486552 (2a), 1486554
(2b), 1486551 (2c), and 1486553 (2d) contain the supplementary
crystallographic data for this paper. These data are provided free
of charge by The Cambridge Crystallographic Data Centre. Experi-
mental data, crystal data, data collection parameters, and structure
refinement details are listed in the Supporting Information (Ta-
bles S1–S14). Molecular structures and packings are displayed in
Figures S5–S8.
ESI-MS measurements
Electrospray ionization mass spectra were recorded on a Bruker
AmaZon SL ion-trap mass spectrometer (Bruker Daltonics GmbH).
Data were acquired and processed using Compass 1.3 and Data
Analysis 4.0 (Bruker Daltonics GmbH). Mass spectra were recorded
following direct infusion with a sample concentration of 5 mm and
a flow rate of 240 mLh1. Small molecules were measured with the
following settings: dry temperature: 180 8C, nebulizer: 8.00 psi, dry
gas: 6.00 Lmin1, and the high-voltage capillary was set to
4500 V or +4500 V for positive and negative mode, respectively.
The target mass was set to 600 m/z. Samples for stability measure-
ments and small molecule samples were diluted with water/metha-
nol (50:50). Stock solutions of complexes 1a–d and 2a–d were
prepared in DMSO and diluted to a final concentration of 1% in
DMSO/H2O. The molar ratios used for interaction studies were
complex:l-histidine:l-cysteine:glycine (1:1:1:1). Mass spectra were
recorded after 0, 1, 3, 6, 24, and 48 h of incubation at 37 8C.
pH-Potentiometric titrations
An Orion 710A pH-meter equipped with a Metrohm combined
electrode (type 6.0234.100) or Metrohm combined double-junction
electrode (type 6.0255.100) and a Metrohm 665 Dosimat burette
were used for the pH-potentiometric measurements. The exact
concentrations of the ligand stock solutions together with the
proton dissociation constants were determined by pH-potentio-
metric titrations with the help of the computer program HYPER-
QUAD.[49] RhCp* stock solutions were obtained by dissolving
a known amount of [RhCp*(m-Cl)Cl]2 in water. A stock solution of
[RhCp*(H2O)3](NO3)2 was obtained from an aqueous solution of
[RhCp*(m-Cl)Cl]2 after removal of chloride ions using an equivalent
amount of AgNO3. Concentrations of RhCp* stock solutions were
checked by pH-potentiometric titrations employing stability con-
stants for [(RhCp*)2(hydroxido)i] (i=2 or 3) complexes.
[22] The pH-
potentiometric measurements were carried out at 25.00.1 8C in
water, and at an ionic strength of 0.20m KCl or KNO3. Titrations
were performed with carbonate-free KOH solution (0.20m). The
exact concentrations of HCl, HNO3, and KOH solutions were deter-
mined by pH-potentiometric titrations. The electrode system was
calibrated to the pH=log [H+] scale by means of blank titrations
(strong acid vs. strong base: HCl/HNO3 vs. KOH), as suggested by
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Irving et al.[50] The average water ionization constant, pKw, was de-
termined as 13.760.01 at 25.0 8C, I=0.20m (KCl, KNO3), which
corresponds well to literature values.[51] The reproducibility of the
titration points included in the calculations was within 0.005 pH
units. The pH-potentiometric titrations were performed in the pH
range between 2.0 and 11.5. The initial volume of the samples was
10.0 mL. The ligand concentration was 1.0 mm and was investigat-
ed at metal ion-to-ligand ratios of 1:1, 1:1.5, and 1:2. The accepted
fitting between the measured and calculated titration data points
regarding the volume of the titrant was < 10 mL. The software PSE-
QUAD[52] was utilized to calculate the stoichiometry of the com-
plexes as well as their overall stability constants. b(MpLqHr) is de-
fined in Equation (1) for the general equilibrium:
pMþ qLþ rH Ð MpLqHr as bðMpLqHrÞ ¼ ½MpLqHr=½ Mp½Lq½Hrð1Þ
where M denotes the metal moiety RhCp* and L is the completely
deprotonated ligand. Values of logß of various
[(RhCp*)2(hydroxido)i] (i=2 or 3) complexes were calculated on the
basis of pH-potentiometric titration data in the absence and pres-
ence of chloride ions, and were in good agreement with our previ-
ously published data.[22]
UV/Vis spectrophotometric and 1H NMR titrations
A Hewlett Packard 8452A diode-array spectrophotometer was
used to record UV/Vis spectra in the interval 200–800 nm. The
pathlength (l) was either 1 or 2 cm. Titrations were performed with
samples containing only thiomaltol (48 mm), RhCp* (48 mm), or
a 1:1 molar ratio of RhCp* and the ligand over the pH range 2.0–
11.5 at an ionic strength of 0.20m (KCl or KNO3) and at 25.0
0.1 8C under anaerobic conditions. Measurements were carried out
in the absence and presence of chloride ions, whereas the 0.20m
KCl or KNO3 was partially or completely replaced by HCl or HNO3,
and pH values in the range 0.7–2.0 were calculated from the con-
tent of strong acid in the solutions. UV/Vis spectra were recorded
to investigate the dependence of the H2O/Cl
 exchange processes
in the [RhCp*(L)(H2O)]
+ complex at pH 3.1 on the Cl concentra-
tion (0–0.64m). Stability constants for the co-ligand exchange were
calculated with the software PSEQUAD.[52] 1H NMR studies were car-
ried out on a Bruker Ultrashield 500 Plus instrument or on
a 600 MHz Bruker Avance III spectrometer equipped with a 5 mm
cryo-TXI (1H, 13C, 15N) probe. All 1H NMR spectra were recorded
with the WATERGATE water suppression pulse scheme using DSS
as an internal standard. Thiomaltol was dissolved in a 10% (v/v)
D2O/H2O mixture to yield a concentration of 1 or 0.1 mm, and each
solution was titrated at 25 8C, at I=0.20m (KCl or KNO3), in the ab-
sence or presence of RhCp* at a 1:1 metal-to-ligand ratio. Samples
containing RhCp* and thiomaltol at various ratios (1:1–1:5) at con-
stant concentration of the ligand (1 mm) at pH 3.85 (I=0.2m KCl)
and 2.70 (I=0.2m KNO3) were measured. Stability (logK) and
proton dissociation (pKa) constants for the complex [ML2H] were
calculated using the software PSEQUAD.[52]
Stability measurements under pH variation
An Eco Scan pH6 pH meter equipped with a glass-micro combina-
tion pH electrode (Orion 9826BN) was used. It was calibrated with
standard buffer solutions of pH 4.00, 7.00, and 10.00. Complexes
2a–d were dissolved in D2O (0.5 mL) and pD values were deter-
mined instantly in the NMR tubes. The pH titrations were per-
formed by addition of NaOD (0.4–0.0004% in D2O) and DCl (0.4–
0.0004% in D2O). After each addition of either DCl or NaOD, the
samples were directly measured at 25 8C using a Bruker Avance IIITM
500 MHz FT-NMR spectrometer. The experimentally obtained pD
values were corrected according to Equation (2)[53] in order to con-
vert the measured values to the corresponding pH values in aque-
ous solution.
pH ¼ 0:936 pH*0:412 ð2Þ
Cell lines and culture conditions
CH1/PA-1 cells (identified by STR profiling as PA-1 ovarian terato-
carcinoma cells by Multiplexion, Heidelberg, Germany) were ob-
tained from Lloyd R. Kelland, CRC Centre for Cancer Therapeutics,
Institute of Cancer Research, Sutton, UK. SW480 (human adenocar-
cinoma of the colon) and A549 (human non-small cell lung cancer)
cells were kindly provided by Brigitte Marian (Institute of Cancer
Research, Department of Medicine I, Medical University of Vienna,
Austria). All cell culture media and reagents were purchased from
Sigma–Aldrich Austria and plastic ware from Starlab Germany. Cells
were grown in 75 cm2 culture flasks as adherent monolayer cul-
tures in Minimum Essential Medium (MEM) supplemented with
10% heat-inactivated fetal calf serum, 1 mm sodium pyruvate,
4 mm l-glutamine, and 1% non-essential amino acids (from 100
ready-to-use stock). Cultures were maintained at 37 8C in humidi-
fied atmosphere composed of 95% air and 5% CO2.
Cytotoxicity assay
Cytotoxic effects of the tested compounds were determined by
means of a colorimetric microculture assay [MTT assay; MTT=3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide].
Cells were harvested from culture flasks by trypsinization and
seeded at densities of 1103 (CH1/PA-1), 2103 (SW480), and 3
103 (A549) in 100 mL per well aliquots in 96-well microculture
plates. Before drug exposure, cells were allowed to settle and
resume proliferation for 24 h. Test compounds were first dissolved
in DMSO, diluted with complete culture medium, and added to
the plates, whereby the final DMSO content did not exceed 0.5%.
After 96 h of exposure, the medium was removed and replaced
with 100 mL/well of a 1:7 MTT/RPMI 1640 solution (MTT solution,
5 mgmL1 of MTT reagent in phosphate-buffered saline;
RPMI 1640 medium, supplemented with 10% heat-inactivated fetal
calf serum (FCS), and 4 mm l-glutamine) and incubated for 4 h at
37 8C. Subsequently, the MTT/RPMI 1640 solution was removed
from all wells, and the formazan crystals formed by viable cells
were dissolved in 150 mL of DMSO per well. Optical densities at
550 nm were measured with a microplate reader (Biotek EL808),
using a reference wavelength of 690 nm to correct for nonspecific
absorption. The quantity of viable cells was expressed in terms of
T/C values (relative to untreated controls), and 50% inhibitory con-
centrations (IC50) were calculated from concentration–effect curves
by interpolation. Evaluation was based on mean values from three
independent experiments.
Topoisomerase IIa inhibition
The topoisomerase IIa inhibitory capacities of the tested com-
pounds were determined by means of a DNA plasmid relaxation
assay. For this purpose, we used a topoisomerase drug screening
kit and human recombinant topoisomerase IIa enzyme from Topo-
Gen Inc. The supercoiled pHOT1 plasmid DNA was incubated for
30 min at 37 8C with topo IIa in the presence of various concentra-
tions of the test compounds. Etoposide (VP-16) was used as a posi-
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tive control at a concentration of 0.8 mm. The reaction was
stopped by the rapid addition of 10% SDS followed by digestion
with proteinase K for 15 min at 37 8C. The samples were divided
and loaded onto two different 1% agarose gels with equal
amounts of reaction products. One gel (Figures 6A and 7A) was
post-stained (after electrophoresis incubated in a 1 TAE buffer
containing 0.7 mgmL1 ethidium bromide) and the other gel (Fig-
ures 6B and 7B) was pre-stained (0.7 mgmL1 ethidium bromide
added to the gel before electrophoresis). Both were analyzed by
visualization with the detection system Fusion SL (Vilber Lourmat).
Evaluation was based on two independent experiments.
Cell cycle studies
For this assay, SW480 cells were harvested by trypsinization and
1.2105 cells were seeded into 12-well plates. In the first 24 h, the
cells were allowed to settle and resume proliferation. Thereafter,
DMSO stock solutions of the tested compounds were diluted with
MEM, and the medium in the plates was replaced with medium
containing the test compounds so that the final DMSO content did
not exceed 0.5%. After continuous exposure for 12 h at 37 8C and
under 5% CO2, the cells were trypsinized and centrifuged at 300 g
for 3 min. They were then washed with PBS (1 mL) and resuspend-
ed in PI/HSF buffer (600 mL; 0.1% Triton X-100, 0.1% sodium cit-
rate, in PBS) containing 50 mgmL1 propidium iodide. After incuba-
tion overnight at 4 8C in the dark, 5103 cells were measured by
flow cytometry with a Millipore guava easyCyte 8HT instrument.
Data were evaluated by means of FlowJo software (Tree Star)
using Dean–Jett–Fox algorithms.
Detection of intracellular reactive oxygen species
DCF-DA (2’,7’-dichlorofluorescein diacetate) was used to detect the
production of ROS. SW480 cells were seeded at densities of 2.5
104 cells in 100 mL/well aliquots in 96-well microculture plates and
were allowed to proliferate for 24 h. The cells were washed with
Hanks’ balanced salt solution (HBSS) supplemented with 1% FCS,
and were stained with 25 mm DCF-DA for 40 min at 37 8C under
5% CO2. The cells were again washed with HBSS supplemented
with 1% FCS, and complexes were added in phenol-red-free MEM
supplemented with 1% FCS at the indicated concentrations. Fluor-
escence measurements were carried out with a Synergy HT micro-
plate reader (BioTek Instruments) set to 37 8C. Measurements were
performed with a 480 nm excitation and a 516 nm emission filter
pair and a PMT sensitivity setting of 50. Readings were conducted
at intervals of 10 min for 120 min. A 200 mm solution of tert-butyl
hydroperoxide (tbHP) was used as a positive control. Background
(non-stained cells) was subtracted from all measurements, and fold
change relative to the untreated control was determined.
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Thiomaltol-Based Organometallic
Complexes with1-Methylimidazole as
Leaving Group: Synthesis, Stability,
and Biological Behavior
En garde! 1-Methylimidazole ligands in
thiomaltol-derived organometallics pro-
tect the complexes from premature de-
composition and are cleaved under
acidic tumor conditions releasing the
active drug (see graphic).
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